NSAIDs Library

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

NSAIDs DMPK and Bioanalytical Services

NSAID bioanalysis is dominated by one enzyme — CYP2C9. Five of seven compounds (ibuprofen, naproxen, diclofenac, ketoprofen, and celecoxib) follow CYP2C9-mediated Phase I metabolism in microsome and hepatocyte models with standard NADPH cofactor. Two do not: aspirin is metabolized by esterases in plasma and microsomes without CYP involvement, and ketorolac is renally excreted unchanged with no metabolic incubation required. A CYP2C9-only protocol applied across all seven will correctly characterize five compounds but will produce zero esterase-mediated metabolite data for aspirin and zero meaningful data for ketorolac — because neither compound uses CYP2C9 as its clearance mechanism.

Creative Proteomics provides CYP2C9-dominant metabolic profiling, esterase metabolism analysis for aspirin, non-metabolized compound disposition for ketorolac, and custom multi-NSAID panels with mechanism-matched incubation arms.

Browse Drug Index Request Custom Method Support

CYP2C9 Dominates Five of Seven NSAIDsIbuprofen, naproxen, diclofenac, ketoprofen, and celecoxib share CYP2C9 as the primary clearance route. A unified CYP2C9 panel serves five.

Aspirin: Esterase, Not CYPMetabolized by esterases in plasma and microsomes. CYP2C9 incubation adds nothing — esterase-stabilized conditions are the analytical requirement.

Ketorolac: Renal, Not MetabolicExcreted unchanged via renal clearance. No CYP or esterase incubation contributes meaningful data for this compound.

NSAID Mechanism Divide DMPK Strategy Map

⚡

Mechanism ClassificationFive CYP2C9 substrates (ibuprofen, naproxen, diclofenac, ketoprofen, celecoxib), one esterase substrate (aspirin), one non-metabolized (ketorolac) — three analytical strategies.

🧬

CYP2C9 Phase I MetabolismFive NSAIDs follow NADPH-supplemented CYP2C9 microsome/hepatocyte incubation. Naproxen adds CYP1A2 as a secondary isoform.

📊

Esterase-Mediated MetabolismAspirin is hydrolyzed by esterases in plasma and microsomes. No CYP involvement. Requires esterase-stabilized, not CYP-supplemented, incubation.

🔬

Non-Metabolized Renal ClearanceKetorolac is excreted unchanged via renal route. Excretion and distribution are the analytical endpoints — no metabolic incubation needed.

NSAID mechanism audit before method development.Creative Proteomics classifies each NSAID as CYP2C9 substrate, esterase substrate, or non-metabolized — because a single CYP2C9 protocol that fits ibuprofen has no relevance to aspirin (esterase) or ketorolac (renal excretion).

NSAID Drug Index

Find the NSAID Compound Behind the Study

NSAID studies split by a key question: CYP2C9 substrate, esterase substrate, or non-metabolized? Five compounds converge on CYP2C9; aspirin requires esterase incubation; ketorolac needs excretion analysis. Use the index to classify the mechanism before method development.

A–Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters.

7 entries · Page 1 of 4

Analytical Pain Points

What Drives Assay Failure in NSAID Studies?

NSAID assays fail when CYP2C9 is assumed to be the universal route. Five compounds use it. Aspirin uses esterases — CYP2C9 is irrelevant. Ketorolac uses renal excretion — metabolism is irrelevant. One generic method misses two compounds completely.

CYP2C9 Serves Five of Seven — Not All Seven

Ibuprofen, naproxen, diclofenac, ketoprofen, and celecoxib are CYP2C9 substrates. Aspirin is esterase-only. Ketorolac is renally excreted. A CYP2C9 panel correctly serves five compounds and is irrelevant to two.

Our responseCYP2C9 NADPH-supplemented incubation for the five CYP substrates, with the two outliers routed to their own mechanism-specific workflows.

Metabolite Identification →

Aspirin Requires Esterase, Not CYP

Aspirin is hydrolyzed by esterases in plasma and microsomes. A NADPH-supplemented CYP2C9 incubation produces zero ASA hydrolysis data because the required enzyme class is not CYP and the cofactor is irrelevant to esterase activity.

Our responseEsterase-stabilized plasma and microsome incubation for aspirin — no NADPH, no CYP isoform panel, esterase-specific substrate monitoring.

Phase I & II Metabolite Characterization →

Ketorolac: No Metabolic Incubation Needed

Ketorolac is excreted unchanged via renal clearance. Plasma, urine, and tissue quantification are the analytical endpoints — CYP or esterase incubation adds no relevant data.

Our responseExcretion- and distribution-focused bioanalysis with renal clearance profiling for ketorolac; no metabolic incubation.

Complex Biological Matrices →

Naproxen Adds CYP1A2 to the CYP2C9 Baseline

Among the five CYP2C9 NSAIDs, naproxen is also a CYP1A2 substrate. A CYP2C9-only incubation captures the primary route but omits secondary CYP1A2 metabolism — producing an incomplete clearance profile.

Our responseMulti-CYP incubation (CYP2C9 + CYP1A2) for naproxen with isoform-selective inhibition controls to quantify CYP1A2 contribution.

Metabolite Identification →

Multi-NSAID Panels Require Three Separate Arms

CYP2C9 incubation (5 NSAIDs), esterase incubation (aspirin), and excretion analysis (ketorolac) — three distinct analytical strategies in one study design, not one pooled protocol.

Our responseMechanism-matched multi-NSAID panels with CYP2C9, esterase, and non-metabolic arms within a single validated study.

Custom Panels →

Focused Service Paths

Four Practical Routes for NSAID Studies

NSAID workflows should be selected by mechanism: CYP2C9 Phase I metabolism for the five CYP substrates; esterase metabolism for aspirin; non-metabolized disposition for ketorolac; or mechanism-matched panels for mixed NSAID studies.

CYP2C9 Phase I Metabolism & MetID

For ibuprofen, naproxen, diclofenac, ketoprofen, and celecoxib — CYP2C9-mediated Phase I metabolism in microsome/hepatocyte models.

CYP2C9 isoform-specific incubation
Multi-CYP for naproxen (CYP2C9 + CYP1A2)
Phase I metabolite profiling

Metabolite Identification →

Esterase Metabolism for Aspirin

Esterase-stabilized plasma and microsome incubation — no CYP cofactor, no NADPH supplementation. Esterase-specific substrate monitoring.

Esterase-stabilized plasma/microsome incubation
Aspirin hydrolysis rate measurement
Salicylic acid metabolite quantification

Phase I & II Metabolite Characterization →

Non-Metabolized NSAID Disposition

For ketorolac — renal excretion and tissue distribution without CYP or esterase incubation.

Plasma and urine unchanged-parent quantification
Renal clearance profiling
No-metabolism workflow validation

Complex Biological Matrices →

Custom Mechanism-Matched NSAID Panel

For multi-NSAID studies with CYP2C9, esterase, and non-metabolized arms in one validated method.

CYP2C9 incubation arm (5 NSAIDs)
Esterase incubation arm (aspirin)
Non-metabolic arm (ketorolac)

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need Support for a Novel or Unlisted NSAID?

If your NSAID follows CYP2C9, esterase, non-metabolized clearance, or a combination — Creative Proteomics builds mechanism-matched workflows before method development.

Creative Proteomics classifies the compound as CYP2C9 substrate, esterase substrate, or non-metabolized — then selects cofactor, enzyme system, and incubation conditions accordingly.

Target NSAID

CYP2C9 / esterase / non-metabolized

Multi-CYP if applicable

Esterase stabilization need

Excretion / distribution focus

Panel requirements

NSAIDs DMPK and Bioanalytical Services

Find the NSAID Compound Behind the Study

What Drives Assay Failure in NSAID Studies?

CYP2C9 Serves Five of Seven — Not All Seven

Aspirin Requires Esterase, Not CYP

Ketorolac: No Metabolic Incubation Needed

Naproxen Adds CYP1A2 to the CYP2C9 Baseline

Multi-NSAID Panels Require Three Separate Arms

Four Practical Routes for NSAID Studies

CYP2C9 Phase I Metabolism & MetID

Esterase Metabolism for Aspirin

Non-Metabolized NSAID Disposition

Custom Mechanism-Matched NSAID Panel

Need Support for a Novel or Unlisted NSAID?

Ready to Quantify Your Lead Compound or Metabolite?